Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Carcinogenicity

Currently viewing:

Administrative data

Description of key information

According to Column 2 of REACH Annex X, a carcinogenicity study may be required if the substance has a widespread dispersive use or there is evidence of frequent or long-term human exposure and the substance is classified as mutagen category 3 or there is evidence from the repeated dose study(ies) that the substance is able to induce hyperplasia and/or pre-neoplastic lesions. The inhalation route is the most likely route of exposure for tungsten carbide and it is not classified as a mutagen and there was no evidence of hyperplasia and/or pre-neoplastic lesions in a 13-week inhalation study on tungsten carbide nor in a 28-day inhalation toxicity study on tungsten oxide, which was used for read-across.

Key value for chemical safety assessment

Carcinogenicity: via oral route

Link to relevant study records
Reference
Endpoint:
carcinogenicity: inhalation
Data waiving:
other justification
Justification for data waiving:
other:
Justification for type of information:
Data waiving
Reason: Other Justification.
Justification: According to Column 2 of REACH Annex X, a carcinogenicity study may be required if the substance has a widespread dispersive use or there is evidence of frequent or long-term human exposure and the substance is classified as mutagen category 3 or there is evidence from the repeated dose study(ies) that the substance is able to induce hyperplasia and/or pre-neoplastic lesions. The inhalation route is the most likely route of exposure for tungsten carbide and it is not classified as a mutagen and there was no evidence of hyperplasia and/or pre-neoplastic lesions in a 13-week inhalation study on tungsten carbide nor in a 28-day inhalation toxicity study on tungsten oxide, which was used for read-across (see Annex 3).
Endpoint conclusion
Endpoint conclusion:
no study available

Carcinogenicity: via inhalation route

Link to relevant study records
Reference
Endpoint:
carcinogenicity: inhalation
Data waiving:
other justification
Justification for data waiving:
other:
Justification for type of information:
Data waiving
Reason: Other Justification.
Justification: According to Column 2 of REACH Annex X, a carcinogenicity study may be required if the substance has a widespread dispersive use or there is evidence of frequent or long-term human exposure and the substance is classified as mutagen category 3 or there is evidence from the repeated dose study(ies) that the substance is able to induce hyperplasia and/or pre-neoplastic lesions. The inhalation route is the most likely route of exposure for tungsten carbide and it is not classified as a mutagen and there was no evidence of hyperplasia and/or pre-neoplastic lesions in a 13-week inhalation study on tungsten carbide nor in a 28-day inhalation toxicity study on tungsten oxide, which was used for read-across (see Annex 3).
Endpoint conclusion
Endpoint conclusion:
no study available

Carcinogenicity: via dermal route

Link to relevant study records
Reference
Endpoint:
carcinogenicity: inhalation
Data waiving:
other justification
Justification for data waiving:
other:
Justification for type of information:
Data waiving
Reason: Other Justification.
Justification: According to Column 2 of REACH Annex X, a carcinogenicity study may be required if the substance has a widespread dispersive use or there is evidence of frequent or long-term human exposure and the substance is classified as mutagen category 3 or there is evidence from the repeated dose study(ies) that the substance is able to induce hyperplasia and/or pre-neoplastic lesions. The inhalation route is the most likely route of exposure for tungsten carbide and it is not classified as a mutagen and there was no evidence of hyperplasia and/or pre-neoplastic lesions in a 13-week inhalation study on tungsten carbide nor in a 28-day inhalation toxicity study on tungsten oxide, which was used for read-across (see Annex 3).
Endpoint conclusion
Endpoint conclusion:
no study available

Justification for classification or non-classification

No carcinogenicity data are available for tungsten carbide. Therefore, classification cannot be made due to lack of data

Additional information